Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer (WAYWIN-301)

13 november 2026 uppdaterad av: Wayshine Biopharm, Inc.

An Open-label, Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of WSD0922-FU Monotherapy Versus Platinum-based Doublet Chemotherapy in Participants With EGFR C797S Mutation-positive, Locally Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy.

This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

196

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200123
        • Shanghai East Hospital
        • Kontakt:
        • Huvudutredare:
          • Caicun Zhou, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Histologically or cytologically confirmed locally advanced or metastatic NSCLC
  2. Eligible for platinum-based doublet chemotherapy
  3. Prior first-line treatment with monotherapy of third-generation EGFR-TKIs (osimertinib, Firmonertinib, Almonertinib, etc.) or third-generation EGFR-TKIs combined with anti-angiogenic drugs or Lazertinib combined with Amivantamab, confirmed by imaging evidence of disease progression, and no other systemic antitumor therapy was administered after progression
  4. Tissue sample confirmed C797S positive by central lab using NGS
  5. At least one measurable target lesion per RECIST v1.1 criteria
  6. ECOG 0-1
  7. Adequate organ function and bone marrow function
  8. Women should take appropriate contraceptive measures and should not breastfeed. If they have fertility, they must undergo a negative pregnancy test before starting medication
  9. Male participants should agree to the use of contraceptive measures

Exclusion Criteria:

  1. Presence of clear bypass tumor driver (e.g., KRAS activating mutations, Braf V600E, MET exon 14 skipping, HER2 mutations, RET fusion, ROS1 fusion etc.)
  2. Histological or phenotypic transformation
  3. Any severe or uncontrolled systemic disease
  4. ≥ Grade 2 toxicities per CTCAE v6.0 attributed to prior anti-tumor therapy except hearing loss, hair loss, and fatigue
  5. Participants with leptomeningeal, brainstem, or spinal cord metastases and/or spinal cord compression, as well as active brain metastases, increased intracranial pressure or associated risks (such as intracranial hemorrhage or intracranial infection), or symptomatic cerebral complications requiring urgent neurosurgical or pharmacological (e.g., mannitol) intervention
  6. A history of interstitial lung disease (ILD), drug-induced ILD, or non-infectious pneumonitis requiring steroid treatment; or suspected ILD or non-infectious pneumonitis that can't be ruled out by imaging at the time of screening
  7. Clinically significant cardiac abnormalities or severe/uncontrolled/active cardiovascular disease
  8. Significant clinical bleeding tendency or history of severe arterial/venous thromboembolic events
  9. Poorly controlled diabetes mellitus or hypertension
  10. History of other primary malignancies within two years
  11. Known active or suspected autoimmune diseases; or known active ocular diseases (such as active wet age-related macular degeneration, diabetic retinopathy with macular edema)
  12. Active infectious diseases (e.g., active HIV, HBV and HCV)
  13. Known alcohol or drug dependence
  14. Mental disorders or poor compliance
  15. The investigator believes that the subject has other reasons that make them unsuitable for participating in this clinical study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: WSD0922-FU Tablet

Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Andra namn:
  • WSD0922
Aktiv komparator: Platinum-Based Doublet Chemotherapy

Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance):

Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle.

Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle.

Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation

Andra namn:
  • Cisplatin
  • Karboplatin
  • Pemetrexed
  • Platinum-based doublet chemotherapy

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression Free Survival (PFS)
Tidsram: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

PFS as assessed by Blinded independent Central Review (BICR) per RECIST 1.1

From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Survival (OS)
Tidsram: From the date of randomization to the date of death from any cause, assessed up to 36 months.

OS

From the date of randomization to the date of death from any cause, assessed up to 36 months.

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
PFS as assessed by investigator per RECIST 1.1
Tidsram: From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
From date of randomization until the date of investigator confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Objective Response Rate (ORR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

ORR as assessed by investigator and BICR per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Duration of Response (DOR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DoR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Disease Control Rate (DCR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

DCR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Disease Progression (TTP)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTP by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Time to Response (TTR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

TTR by BICR and Investigator per RECIST 1.1

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial ORR (icORR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icORR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial PFS (icPFS)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icPFS by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DOR (icDOR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDOR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial DCR (icDCR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icDCR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTP (icTTP)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTP by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Intracranial TTR (icTTR)
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

icTTR by BICR and Investigator per RANO-BM

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
AE and SAE
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

AE and SAE per CTCAE 6.0

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-C30 test results from a minimum of 0 to a maximum of 100, where higher scores represent either a better or worse outcome depending on the specific subscale

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13
Tidsram: From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Quality of life according to the EORTC QLQ-LC13 test results from a minimum of 0 to a maximum of 100, where higher scores indicate a worse outcome

From date of randomization until the date of progression or date of death from any cause, whichever comes first, assessed up to 24 months.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Caicun Zhou, MD, Shanghai East Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

10 december 2026

Primärt slutförande (Beräknad)

1 maj 2028

Avslutad studie (Beräknad)

31 oktober 2029

Studieregistreringsdatum

Först inskickad

8 november 2026

Först inskickad som uppfyllde QC-kriterierna

13 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 november 2026

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera